Fintel reports that on May 7, 2026, Wells Fargo upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from Equal-Weight to Overweight.
Analyst Price Forecast Suggests 8.60% Upside
As of April 28, 2026, the average one-year price target for United Therapeutics is $648.10/share. The forecasts range from a low of $524.19 to a high of $769.65. The average price target represents an increase of 8.60% from its latest reported closing price of $596.76 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for United Therapeutics is 2,609MM, a decrease of 17.69%. The projected annual non-GAAP EPS is 25.71.
What is the Fund Sentiment?
There are 854 funds or institutions reporting positions in United Therapeutics. This is an decrease of 429 owner(s) or 33.44% in the last quarter. Average portfolio weight of all funds dedicated to UTHR is 0.22%, an increase of 28.51%. Total shares owned by institutions decreased in the last three months by 11.72% to 42,130K shares. 
The put/call ratio of UTHR is 0.74, indicating a bullish outlook.
What are Other Shareholders Doing?
Avoro Capital Advisors holds 2,606K shares representing 5.95% ownership of the company. In its prior filing, the firm reported owning 2,022K shares , representing an increase of 22.40%. The firm increased its portfolio allocation in UTHR by 13.90% over the last quarter.
Wellington Management Group Llp holds 2,441K shares representing 5.57% ownership of the company. In its prior filing, the firm reported owning 1,399K shares , representing an increase of 42.71%. The firm decreased its portfolio allocation in UTHR by 71.23% over the last quarter.
Renaissance Technologies holds 1,909K shares representing 4.36% ownership of the company. In its prior filing, the firm reported owning 2,173K shares , representing a decrease of 13.83%. The firm increased its portfolio allocation in UTHR by 19.99% over the last quarter.
Aqr Capital Management holds 1,282K shares representing 2.92% ownership of the company. In its prior filing, the firm reported owning 986K shares , representing an increase of 23.03%. The firm decreased its portfolio allocation in UTHR by 70.87% over the last quarter.
Geode Capital Management holds 1,193K shares representing 2.72% ownership of the company. In its prior filing, the firm reported owning 1,250K shares , representing a decrease of 4.74%. The firm increased its portfolio allocation in UTHR by 7.34% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
